MedTrace Logo

The Effect of Semaglutide on Pituitary Function

NCT04865744 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-02-22

No results posted yet for this study

Summary

The primary aim of the study is to describe the effect of a single oral dose of semaglutide 7 mg on growth hormone secretion.

Conditions

  • Healthy

Interventions

DRUG

Semaglutide 7 MG Oral Tablet

Semaglutide 7 mg oral tablet taken after an overnight fast with up to 120 ml of water.

DRUG

Placebo

Placebo tablet is taken after an overnight fast with up to120 ml of water.

DRUG

Semaglutide 14 MG Oral Tablet

Semaglutide 14 mg oral tablet taken after an overnight fast with up to 120 ml water.

Sponsors & Collaborators

  • University of Tartu

    lead OTHER

Principal Investigators

  • Vallo Volke, MD, PhD · University of Tartu

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-19
Primary Completion
2021-09-23
Completion
2021-09-30

Countries

  • Estonia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04865744 on ClinicalTrials.gov